Related Experiment Videos
Coronary intervention and glycoprotein IIb/IIIa integrin blockade
1Duke Clinical Research Institute, Durham, North Carolina 27710, USA.
Coronary Artery Disease
|December 22, 1999
Summary
Platelet glycoprotein IIb/IIIa receptor antagonists are crucial for reducing adverse cardiovascular events during percutaneous coronary intervention (PCI). Clinical trials confirm their effectiveness, establishing them as vital treatments.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Platelet glycoprotein IIb/IIIa receptor antagonists have rapidly evolved from experimental compounds to essential treatments.
- Percutaneous coronary intervention (PCI) is a common procedure for treating coronary artery disease.
Purpose of the Study:
- To examine and interpret results from large-scale clinical trials of glycoprotein IIb/IIIa inhibition during PCI.
- To review future research directions for this class of therapeutic agents.
Main Methods:
- Analysis of data from over 15,000 patients in clinical trials involving glycoprotein IIb/IIIa antagonists during PCI.
- Review of studies on specific agents like abciximab, eptifibatide, and tirofiban.
Main Results:
- Glycoprotein IIb/IIIa blockade significantly reduces adverse cardiovascular sequelae following PCI.
- Abciximab is the most studied agent, but eptifibatide and tirofiban also demonstrate class utility.
Conclusions:
- Glycoprotein IIb/IIIa receptor antagonists are proven effective in reducing cardiovascular complications after PCI.
- Further research is warranted to explore the full potential of these agents.